763P Re-VOLVE: Phase II trial in women with ovarian cancer progressing post-PARP-inhibitor with treatment adapted to real-time assessment of evolving genomic resistance.
Saved in:
| Title: | 763P Re-VOLVE: Phase II trial in women with ovarian cancer progressing post-PARP-inhibitor with treatment adapted to real-time assessment of evolving genomic resistance. |
|---|---|
| Authors: | Soberanis Pina, P.D.1 (AUTHOR), Oza, A.M.2 (AUTHOR), Dhani, N.3 (AUTHOR), Wang, L.4 (AUTHOR), Grant, R.5 (AUTHOR), Garg, V.1 (AUTHOR), Lee, J-S.6 (AUTHOR), Benito, C.7 (AUTHOR), Selim, F.R.8 (AUTHOR), Arora, S.9 (AUTHOR), Ramsahai, J.10 (AUTHOR), Quintos, J.11 (AUTHOR), Dhanabalan, P.12 (AUTHOR), Bowering, V.13 (AUTHOR), Lam, B.14 (AUTHOR), Thiagarajah, M.15 (AUTHOR), Fortuna, A.15 (AUTHOR), Pugh, T.16 (AUTHOR), Lheureux, S.3 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS577-S578. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2024.08.824 |
